IGC Pharma Statistics
Total Valuation
IGC Pharma has a market cap or net worth of $32.53 million. The enterprise value is $31.35 million.
| Market Cap | 32.53M |
| Enterprise Value | 31.35M |
Important Dates
The next estimated earnings date is Thursday, August 8, 2024, after market close.
| Earnings Date | Aug 8, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
IGC Pharma has 75.64 million shares outstanding. The number of shares has increased by 11.91% in one year.
| Shares Outstanding | 75.64M |
| Shares Change (YoY) | +11.91% |
| Shares Change (QoQ) | +0.81% |
| Owned by Insiders (%) | 8.18% |
| Owned by Institutions (%) | 21.39% |
| Float | 69.43M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 24.19 |
| Forward PS | 23.01 |
| PB Ratio | 4.44 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 23.31 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.58, with a Debt / Equity ratio of 0.03.
| Current Ratio | 1.58 |
| Quick Ratio | 0.62 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -119.10% and return on invested capital (ROIC) is -129.91%.
| Return on Equity (ROE) | -119.10% |
| Return on Assets (ROA) | -97.50% |
| Return on Capital (ROIC) | -129.91% |
| Revenue Per Employee | $20,075 |
| Profits Per Employee | -$194,030 |
| Employee Count | 67 |
| Asset Turnover | 0.10 |
| Inventory Turnover | 0.29 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +35.26% in the last 52 weeks. The beta is 1.51, so IGC Pharma's price volatility has been higher than the market average.
| Beta (5Y) | 1.51 |
| 52-Week Price Change | +35.26% |
| 50-Day Moving Average | 0.48 |
| 200-Day Moving Average | 0.37 |
| Relative Strength Index (RSI) | 47.16 |
| Average Volume (20 Days) | 201,463 |
Short Selling Information
The latest short interest is 1.33 million, so 1.75% of the outstanding shares have been sold short.
| Short Interest | 1.33M |
| Short Previous Month | 1.33M |
| Short % of Shares Out | 1.75% |
| Short % of Float | 1.91% |
| Short Ratio (days to cover) | 4.15 |
Income Statement
In the last 12 months, IGC Pharma had revenue of $1.35 million and -$13.00 million in losses. Loss per share was -$0.22.
| Revenue | 1.35M |
| Gross Profit | 733,000 |
| Operating Income | -9.80M |
| Pretax Income | -13.00M |
| Net Income | -13.00M |
| EBITDA | -12.36M |
| EBIT | -13.00M |
| Loss Per Share | -$0.22 |
Balance Sheet
The company has $1.41 million in cash and $221,000 in debt, giving a net cash position of $1.19 million or $0.02 per share.
| Cash & Cash Equivalents | 1.41M |
| Total Debt | 221,000 |
| Net Cash | 1.19M |
| Net Cash Per Share | $0.02 |
| Equity (Book Value) | 7.32M |
| Book Value Per Share | 0.10 |
| Working Capital | 1.37M |
Cash Flow
In the last 12 months, operating cash flow was -$5.20 million and capital expenditures -$94,000, giving a free cash flow of -$5.29 million.
| Operating Cash Flow | -5.20M |
| Capital Expenditures | -94,000 |
| Free Cash Flow | -5.29M |
| FCF Per Share | -$0.09 |
Margins
Gross margin is 54.50%, with operating and profit margins of -728.48% and -966.54%.
| Gross Margin | 54.50% |
| Operating Margin | -728.48% |
| Pretax Margin | -966.54% |
| Profit Margin | -966.54% |
| EBITDA Margin | -919.18% |
| EBIT Margin | -966.54% |
| FCF Margin | -393.53% |
Dividends & Yields
IGC Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -11.91% |
| Shareholder Yield | -11.91% |
| Earnings Yield | -39.96% |
| FCF Yield | -16.27% |
Analyst Forecast
The average price target for IGC Pharma is $3.25, which is 655.64% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $3.25 |
| Price Target Difference | 655.64% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on April 19, 2013. It was a reverse split with a ratio of 1:10.
| Last Split Date | Apr 19, 2013 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
IGC Pharma has an Altman Z-Score of -12.54 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -12.54 |
| Piotroski F-Score | 4 |